# EDGAR Filing Document

**Accession Number:** 0000070487
**File Stem:** 0001437749-26-015083
**Filing Date:** 2026-5
**Character Count:** 83465
**Document Hash:** 466624f88ce692816f9f6a3298b59ef5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-015083.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001437749-26-015083

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 57

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NRC HEALTH
- **CENTRAL INDEX KEY:** 0000070487
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 470634000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35929
- **FILM NUMBER:** 26947002

**BUSINESS ADDRESS:**
- **STREET 1:** 1245 Q STREET
- **CITY:** LINCOLN
- **STATE:** NE
- **ZIP:** 68508
- **BUSINESS PHONE:** 4024752525

**MAIL ADDRESS:**
- **STREET 1:** 1245 Q STREET
- **CITY:** LINCOLN
- **STATE:** NE
- **ZIP:** 68508

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NATIONAL RESEARCH CORP
- **DATE OF NAME CHANGE:** 19970715

?xml version='1.0' encoding='ASCII'? nrc20260331_10q.htm

[<u>**Table of Contents**</u>](#toc)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

---

| | |
|:---|:---|
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|  | For the quarterly period ended March 31, 2026 |

---

or

---

| | |
|:---|:---|
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|  | For the transition period from ________ to ________ |

---

Commission File Number **<u>001-35929</u>**

**NRC Health**<br>

(Exact name of Registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **47-0634000** |
| (State or other jurisdiction of | (I.R.S. Employer |
| incorporation or organization) | Identification No.) |

---

---

| |
|:---|
| **1245 Q Street, Lincoln, Nebraska** &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **68508** |
| (Address of principal executive offices) (Zip Code) |

---

---

| |
|:---|
| **(402) 475-2525** |
| (Registrant's telephone number, including area code) |

---

---

| |
|:---|
| **National Research Corporation** |
| (Former name, former address and former fiscal year, if changed since last report) |

---

Securities registered pursuant to 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $.001 par value | NRC | The NASDAQ stock market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer &nbsp;&nbsp;&nbsp;&nbsp; | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock as of the latest practicable date.

<u>Common Stock, $.001 par value, outstanding as of April 30, 2026: 22,536,696</u>

------

[**Table of Contents**](#toc)

**NRC HEALTH**

**FORM 10-Q INDEX**

**For the Quarter Ended March 31, 2026**

---

| | | | |
|:---|:---|:---|:---|
|  | | | <u>Page</u><br> <u>No.</u> |
| PART I. | [<u>FINANCIAL INFORMATION</u>](#part1) | [<u>FINANCIAL INFORMATION</u>](#part1) |  |
|  | Item 1. | [<u>Financial Statements</u>](#part1) | [3](#part1) |
|  |  | [<u>Condensed Consolidated Balance Sheets</u>](#part1) | [3](#part1) |
|  |  | [<u>Condensed Consolidated Statements of Income</u>](#stateofincome) | [4](#stateofincome) |
|  |  | [<u>Condensed Consolidated Statements of Shareholders</u><u>'</u> <u>Equity</u>](#equity) | [5](#equity) |
|  |  | [<u>Condensed Consolidated Statements of Cash Flows</u>](#cashflows) | [7](#cashflows) |
|  |  | [<u>Notes to Condensed Consolidated Financial Statements</u>](#notes) | [<u>9</u>](#notes)-[7](#NotesEnd) |
|  | Item 2. | [<u>Management</u><u>'</u><u>s Discussion and Analysis of</u> <u>Financial Condition and Results of Operations</u>](#item2mda) | [<u>15</u>](#item2mda)-[21](#MdaEnd) |
|  | Item 3. | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#item3qandq) | [22](#item3qandq) |
|  | Item 4. | [<u>Controls and Procedures</u>](#item4conandpro) | [22](#item4conandpro) |
| PART II. | [<u>OTHER INFORMATION</u>](#part2) | [<u>OTHER INFORMATION</u>](#part2) |  |
|  | Item 1. | [<u>Legal Proceedings</u>](#item1) | [22](#item1) |
|  | Item 1A. | [<u>Risk Factors</u>](#item1a) | [22](#item1a) |
|  | Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item2) | [23](#item2) |
|  | Item 5. | [<u>Other Information</u>](#item5) | [23](#item5) |
|  | Item 6. | [<u>Exhibits</u>](#item6) | [24](#item6) |
|  | [<u>Signatures</u>](#sigs) | [<u>Signatures</u>](#sigs) | [25](#sigs) |

---

------

[**Table of Contents**](#toc)

**<u>Special Note Regarding Forward-Looking Statements</u>**

Certain matters discussed in this Quarterly Report on Form 10-Q are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can generally be identified as such because the context of the statement includes phrases such as NRC Health, formerly known as National Research Corporation ("the Company," "we," "our," "us" or similar terms), "believes," "expects," "may," "could," "anticipates," "estimates," "plans," "creates," "intends," or the use of words such as "would," "will," "may," "could," "goal," "focus," or "should," or other words of similar import. Similarly, statements that describe our future plans, objectives or goals are also forward-looking statements. In this Quarterly Report on Form 10-Q, statements regarding the value and utility of, and market demand for, our service offerings, future opportunities for growth with respect to new and existing customers, our future ability to compete and the types of firms with which we will compete, future consolidation in the healthcare industry, future adequacy of our liquidity sources, future revenue sources, future revenue, expenses, and margins, future revenue estimates used to calculate total recurring contract value, the expected impact of economic factors, including interest rates and inflation, future capital expenditures, and the timing, amount, and sources of cash to fund such capital expenditures, future stock repurchases and dividends, the expected impact of pending claims and contingencies, the future outcome of uncertain tax positions, future non-cash charges related to executive equity awards, our future use of owned and leased real property, and the expected impact of global conflicts, among others, are forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties which could cause actual results or outcomes to differ materially from those currently anticipated. Factors that could affect actual results or outcomes include, without limitation, the following factors:

● The possibility of non-renewal of our customer service contracts, reductions in services purchased or prices, and failure to retain key customers;

● Our ability to compete in our markets, which are highly competitive with new market entrants and subject to consolidation among existing competitors, and the possibility of increased price pressure and expenses;

● The possibility that our solutions and technology do not perform as expected;

● The possibility that our acquisitions and partnerships do not achieve the increased demand/profitability expected;

● The likelihood that a pandemic will adversely affect our operations, sales, earnings, financial condition, and liquidity;

● The likelihood that global conflicts or tariffs will adversely affect our operations, sales, earnings, financial condition, and liquidity;

● The effects of an economic downturn;

● The impact of consolidation in the healthcare industry;

● The impact of federal healthcare and budget legislation, executive orders, cost-saving measures, and other regulatory changes;

● Our ability to attract and retain key managers and other personnel;

● The possibility that our intellectual property and other proprietary information technology could be copied or independently developed by our competitors;

● Our ability to maintain effective internal controls;

● The possibility for failures or deficiencies in our information technology platform;

● The possibility that we or our third-party providers could be subject to cyber-attacks, security breaches, or computer viruses; and 

● The factors set forth under the caption "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K, as such section may be updated or supplemented by Part II, Item 1A of our subsequently filed Quarterly Reports on Form 10-Q (including this Report) and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission.

Shareholders, potential investors, and other readers are urged to consider these and other factors in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included are only made as of the date of this Quarterly Report on Form 10-Q and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances, except as required by the federal securities laws.

------

[**Table of Contents**](#toc)

**PART I** – **Financial Information**

ITEM 1. <u>Financial Statements</u>

**NRC HEALTH**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

(In thousands, except share amounts and par value)

---

| | | |
|:---|:---|:---|
|  | March 31,<br> 2026 | December 31,<br> 2025 |
|  | (unaudited) |  |
| <u>**Assets**</u> |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $2547 | $4139 |
| Trade accounts receivable, less allowance for credit losses of $90 and $80, respectively | 10833 | 11108 |
| Prepaid expenses | 5662 | 3914 |
| Income taxes receivable | 481 | 528 |
| Other current assets | 461 | 520 |
| Total current assets | 19984 | 20209 |
| Property and equipment, net | 40305 | 40474 |
| Intangible assets, net | 2165 | 2227 |
| Goodwill | 66152 | 66152 |
| Deferred contract costs, net | 3123 | 2498 |
| Other noncurrent assets | 2830 | 3318 |
| Total assets | $134559 | $134878 |
| **<u>Liabilities and Shareholders</u>**<u>'</u> **<u>Equity</u>** |  |  |
| Current liabilities: |  |  |
| Current portion of notes payable, net of unamortized debt issuance costs | $4015 | $4014 |
| Accounts payable | 2227 | 1169 |
| Accrued wages and bonuses | 6603 | 7218 |
| Accrued expenses | 2582 | 2897 |
| Dividends payable | 3606 | 3625 |
| Deferred revenue | 17192 | 16201 |
| Income taxes payable | 1768 | 550 |
| Other current liabilities | 477 | 946 |
| Total current liabilities | 38470 | 36620 |
| Notes payable, net of current portion and unamortized debt issuance costs | 74017 | 75021 |
| Deferred income taxes | 5999 | 5984 |
| Other long-term liabilities | 2578 | 3263 |
| Total liabilities | 121064 | 120888 |
| Shareholders' equity: |  |  |
| Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued |  |  |
| Common stock, $0.001 par value; authorized 110,000,000 shares, issued 31,975,649 in 2026 and 31,966,504 in 2025, outstanding 22,536,696 in 2026 and 22,637,252 in 2025 | 32 | 32 |
| Additional paid-in capital | 185627 | 183880 |
| Retained earnings (accumulated deficit) | (17682) | (17298) |
| Treasury stock, at cost; 9,438,953 and 9,329,252 Common shares in 2026 and 2025, respectively | (154482) | (152624) |
| Total shareholders' equity | 13495 | 13990 |
| Total liabilities and shareholders' equity | $134559 | $134878 |

---

See accompanying notes to condensed consolidated financial statements.

------

[**Table of Contents**](#toc)

**NRC HEALTH**

**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**

(In thousands, except for per share amounts, unaudited)

---

| | | |
|:---|:---|:---|
|  | Three months ended<br> March 31, | Three months ended<br> March 31, |
|  | 2026 | 2025 |
| Revenue | $34803 | $33551 |
| Operating expenses: |  |  |
| Direct | 13646 | 13057 |
| Selling, general, and administrative | 13419 | 10356 |
| Depreciation and amortization | 2169 | 1542 |
| Total operating expenses | 29234 | 24955 |
| Operating income | 5569 | 8596 |
| Other income (expense): |  |  |
| Interest income | 35 | 19 |
| Interest expense | (1255) | (899) |
| Other, net | 30 | 7 |
| Total other expense | (1190) | (873) |
| Income before income taxes | 4379 | 7723 |
| Provision for income taxes | 1157 | 1936 |
| Net income | $3222 | $5787 |
| Earnings per share of common stock: |  |  |
| Basic | $0.14 | $0.25 |
| Diluted | $0.14 | $0.25 |
| Weighted average shares and share equivalents outstanding: |  |  |
| Basic | 21799 | 22972 |
| Diluted | 21911 | 22974 |

---

See accompanying notes to condensed consolidated financial statements.

------

[**Table of Contents**](#toc)

**NRC HEALTH**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS**' **EQUITY**

(In thousands except share and per share amounts, unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common<br> Stock**  | **Additional<br> Paid-in<br> Capital** | **Retained<br> Earnings**<br> **(Deficit)** | **Treasury**<br> **Stock**  | **Total** |
| Balances at December 31, 2025 | $32 | $183880 | $(17298) | $(152624) | $13990 |
| Purchase of 109,701 shares treasury stock |  |  |  | (1858) | (1858) |
| Issuance of 9,145 shares of common stock for the exercise of stock options |  | 139 |  |  | 139 |
| Non-cash stock compensation expense |  | 1608 |  |  | 1608 |
| Dividends declared of $0.16 per share of common stock |  |  | (3606) |  | (3606) |
| Net income |  |  | 3222 |  | 3222 |
| Balances at March 31, 2026 | $32 | $185627 | $(17682) | $(154482) | $13495 |

---

See accompanying notes to condensed consolidated financial statements.

------

[**Table of Contents**](#toc)

**NRC HEALTH**

**CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS**' **EQUITY**

(In thousands except share and per share amounts, unaudited)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common<br> Stock**  | **Additional<br> Paid-in<br> Capital** | **Retained<br> Earnings**<br> **(Deficit)** | **Treasury**<br> **Stock**  | **Total** |
| Balances at December 31, 2024 | $31 | $180249 | $(17064) | $(131932) | $31284 |
| Purchase of 307,709 shares treasury stock |  |  |  | (4967) | (4967) |
| Issuance of 10,014 shares of common stock for the exercise of stock options |  | 132 |  |  | 132 |
| Non-cash stock compensation expense |  | 171 |  |  | 171 |
| Dividends declared of $0.12 per share of common stock |  |  | (2735) |  | (2735) |
| Net income |  |  | 5787 |  | 5787 |
| Balances at March 31, 2025 | $31 | $180552 | $(14012) | $(136899) | $29672 |

---

See accompanying notes to condensed consolidated financial statements.

------

[**Table of Contents**](#toc)

**NRC HEALTH**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In thousands, unaudited)

---

| | | |
|:---|:---|:---|
|  | Three months ended | Three months ended |
|  | March 31, | March 31, |
|  | 2026 | 2025 |
| Cash flows from operating activities: |  |  |
| Net income | $3222 | $5787 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| Depreciation and amortization | 2169 | 1542 |
| Deferred income tax expense (benefit) | (36) | 1860 |
| Reserve for uncertain tax positions | (56) | 76 |
| Non-cash share-based compensation expense | 1608 | 171 |
| Change in fair value of contingent consideration |  | 31 |
| Loss on extinguishment of debt |  | 67 |
| Amortization of debt issuance costs | 27 | 15 |
| Net changes in assets and liabilities: |  |  |
| Trade accounts receivable | 275 | (272) |
| Prepaid expenses and other current and long-term assets | (1627) | (2419) |
| Deferred contract costs, net | (625) | 24 |
| Operating lease assets and liabilities, net | (30) | (26) |
| Accounts payable | 942 | 627 |
| Accrued expenses, wages, and bonuses | (889) | (472) |
| Income taxes receivable and payable | 1265 | (80) |
| Deferred revenue | 935 | (285) |
| Net cash provided by operating activities | 7180 | 6646 |
| Cash flows from investing activities: |  |  |
| Capital expenditures | (1834) | (2986) |
| Net cash used in investing activities | (1834) | (2986) |
| Cash flows from financing activities: |  |  |
| Borrowings on notes payable |  | 27738 |
| Payments on notes payable | (1030) | (28724) |
| Borrowings on revolving loan | 2500 | 8000 |
| Payments on revolving loan | (2500) | (4503) |
| Payment of debt issuance costs |  | (62) |
| Payments on finance lease obligations | (3) | (2) |
| Proceeds from the exercise of share-based awards | 139 | 132 |
| Payment of acquisition contingent consideration | (484) | (280) |
| Repurchase of shares for treasury | (1935) | (4920) |
| Payment of dividends on common stock | (3625) | (2770) |
| Net cash used in financing activities | (6938) | (5391) |
| Change in cash and cash equivalents | (1592) | (1731) |
| Cash and cash equivalents at beginning of period | 4139 | 4233 |
| Cash and cash equivalents at end of period | $2547 | $2502 |

---

See accompanying notes to condensed consolidated financial statements.

------

[**Table of Contents**](#toc)

**NRC HEALTH**

**CONSOLIDATED STATEMENTS OF CASH FLOWS, Continued**

(In thousands)

---

| | | |
|:---|:---|:---|
|  | Three months ended | Three months ended |
|  | March 31, | March 31, |
|  | 2026 | 2025 |
| Supplemental disclosure of cash paid for: |  |  |
| Interest expense, net of capitalized amounts | $1247 | $774 |
| Income taxes |  | $80 |
| Income taxes (federal) | $- |  |
| Income taxes (state and local) | $26 |  |
| Supplemental disclosure of non-cash investing and financing activities: |  |  |
| Purchase of property and equipment in accounts payable and accrued expenses | $450 | $2131 |
| Repurchase of shares for treasury in accounts payable and accrued expenses | $151 | $47 |
| Debt issuance costs included in accrued expenses | $- | $81 |
| New debt issued to existing lender | $- | $34396 |
| Debt extinguished using proceeds from new debt | $- | $62076 |
| Noncash borrowings on long-term debt for accrued interest and debt issuance costs | $- | $351 |

---

See accompanying notes to condensed consolidated financial statements.

------

[**Table of Contents**](#toc)

**NRC HEALTH**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(1)** **<u>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u>**

**Basis of Presentation**

Our condensed consolidated balance sheet at December 31, 2025, was derived from our audited consolidated balance sheet as of that date. All other financial statements contained herein are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments) that we consider necessary for a fair presentation of financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States.

Information and footnote disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto that are included in our Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on March 15, 2026.

**Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

**Deferred Contract Costs** 

We defer incremental costs of obtaining customer contracts. These costs are amortized over the estimated term of the contract, including renewals, which generally ranges from three to five years. We deferred incremental costs of obtaining a contract of $908,000 and $354,000 in the three-month periods ended March 31, 2026, and 2025, respectively. Deferred contract costs, net of accumulated amortization was $3.1 million and $2.5 million at March 31, 2026, and December 31, 2025, respectively. Total amortization by expense classification for the three-month periods ended March 31, 2026, and 2025 was as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | 2026 | 2025 |
| Direct expenses | $32 | $20 |
| Selling, general, and administrative expenses | $240 | $356 |
| Total amortization | $272 | $376 |

---

**Fair Value Measurements**

Our contingent consideration liability was measured at fair value on a recurring basis using significant unobservable inputs (Level 3). The measurement period for the contingent consideration arrangement was completed as of December 31, 2025. The remaining liability was settled during the quarter and no balance remained at March 31, 2026.

**Commitments and Contingencies**

There were no material changes to the Company's commitments, contingencies, or legal proceedings from those disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

**Recently Adopted Accounting Standards**

We elected the practical expedient under ASU 2025-05 to estimate expected credit losses for current accounts receivable and current contract assets by assuming current conditions as of the balance-sheet date remain unchanged over the remaining life of the assets. The adoption and election did not have a material impact on our condensed consolidated financial statements or related disclosures.

------

[**Table of Contents**](#toc)

**Recent Accounting Pronouncements Not Yet Adopted**

We monitor recently issued accounting pronouncements to assess their potential impact on our consolidated financial statements and related disclosures. The following Accounting Standards Updates ("ASUs") have been issued but not yet adopted. The Company has evaluated or is currently evaluating each standard to determine the impact of adoption.

In February 2024, the FASB issued ASU 2024-03, which provides improvements to the disclosure requirements for expenses. The update primarily impacts disclosures by requiring entities to provide additional detail about the natural classification of significant expenses that are included in relevant income statement line items. ASU 2024-03 is effective for the Company for annual reporting periods beginning after December 15, 2026, and interim periods thereafter. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial position or results of operations, but it will result in expanded expense disclosures beginning with the Company's annual financial statements for the year ending December 31, 2027.

In September 2025, the FASB issued ASU 2025-06, which provides targeted improvements to the accounting for internal-use software. The update replaces the current project stage model with a principles-based framework and requires capitalization to begin when management authorizes and commits funding, and project completion is probable. ASU 2025-06 is effective for the Company for annual reporting periods beginning after December 15, 2027, including interim periods within those years. The Company is currently evaluating the effect of adopting this standard, and the impact is not yet known or reasonably estimable. The Company will determine the transition method for adoption and does not plan to adopt before the effective date.

**(2)** **<u>CONTRACTS WITH CUSTOMERS</u>**

We derive a majority of our revenue from renewable subscription-based service agreements with our customers. These arrangements represent a single promise to stand ready to provide services over the contractual term and are recognized ratably as the related services are provided. As a result, the significant majority of our revenue is recognized over time.

Revenue recognized over time totaled $33.3 million and $31.0 million for the three months ended March 31, 2026 and 2025, respectively. Revenue associated with performance obligations satisfied at a point in time, including one-time specified services, as well as revenue from fixed, non-subscription and unit-priced service arrangements, was not material for either period.

Total revenue for the three months ended March 31, 2026, was $34.8 million, compared to $33.6 million for the three months ended March 31, 2025, with the increase primarily attributable to growth in subscription-based services.

Our revenue recognition patterns during the quarter are consistent with those disclosed in our Annual Report on Form 10-K.

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers (in thousands):

---

| | | |
|:---|:---|:---|
|  | March 31,<br> 2026 | December 31,<br> 2025 |
| Trade accounts receivables | $10833 | $11108 |
| Contract assets included in other current assets | $75 | $132 |
| Deferred revenue, current portion | $17192 | $16201 |
| Noncurrent deferred revenue included in other long-term liabilities | $18 | $74 |

---

Deferred revenue increased by $1.0 million primarily due to new billings exceeding revenue recognized during the period.

We have elected to apply the practical expedient to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Total remaining contract revenue for contracts with original duration of greater than one year expected to be recognized in the future related to performance obligations that are unsatisfied at March 31, 2026, approximated $194.5 million, of which $61.5 million is expected to be recognized over the next 12 months, with the remainder recognized thereafter.

------

[**Table of Contents**](#toc)

**(3)** **<u>INCOME TAXES</u>**

The effective tax rate was 26% and 25% for the three-month periods ended March 31, 2026, and 2025, respectively. The increase in the effective tax rate was primarily driven by a higher impact from non-deductible executive compensation under IRC Section 162(m).

**(4)** **<u>NOTES PAYABLE</u>**

Our long-term debt consists of amounts outstanding under the Credit Agreement entered into in February 2025, as described in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. There were no amendments, modifications, or new debt issuances during the three months ended March 31, 2026. Our long-term debt consists of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | March 31,<br> 2026 | December 31,<br> 2025 |
| Delayed Draw Term Loan | $78376 | $79406 |
| Less: current portion | (4015) | (4014) |
| Less: unamortized debt issuance costs | (344) | (371) |
| Notes payable, net of current portion | $74017 | $75021 |

---

As of March 31, 2026, we were in compliance with all financial covenants.

**(5)** **<u>SHARE-BASED COMPENSATION</u>**

Our 2025 Omnibus Incentive Plan (the "2025 Omnibus Incentive Plan"), which became effective on May 7, 2025, provides for the granting of equity-based awards, as described in our Annual Report on Form 10-K for the year ended December 31, 2025. At March 31, 2026, 3.9 million shares of common stock were available for issuance pursuant to future grants under the plan.

*Service-Based Stock Option Awards*

We grant stock options to directors and select executives with vesting based on specified service periods. Vesting terms vary with each grant and option awards are generally five to ten years following the date of grant. We recognize compensation expense on a straight-line basis over the service period specified in the award. We granted 17,638 and 11,021 service-based stock option awards during the three-month period ended March 31, 2026 and 2025, respectively.

The fair value of service-based stock options granted in 2026 was estimated using a Black-Scholes valuation model with the following weighted average assumptions:

---

| | |
|:---|:---|
|  | 2026 |
| Expected dividend yield at date of grant | 3.49% |
| Expected stock price volatility | 34.51% |
| Risk-free interest rate | 3.85% |
| Expected life of options (in years) | 5.0 |

---

The risk-free interest rate assumptions were based on the U.S. Treasury yield curve in effect at the time of the grant. The expected volatility was based on historical monthly price changes of our stock based on the expected life of the options at the date of grant. The expected life of options is the average number of years we estimate that options will be outstanding. We consider groups of associates that have similar historical exercise behavior separately for valuation purposes.

------

[**Table of Contents**](#toc)

The following table summarizes service-based stock option activity for the three-month period ended March 31, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Number of<br> Options | Weighted<br> Average<br> Exercise<br> Price | Weighted<br> Average<br> Remaining<br> Contractual<br> Terms<br> (Years) | Aggregate<br> Intrinsic<br> Value<br> (In<br> thousands) |
| Outstanding at December 31, 2025 | 608782 | $27.52 |  |  |
| Granted | 17638 | $22.01 |  |  |
| Exercised | 9145 | $15.23 |  |  |
| Expired |  |  |  |  |
| Forfeited |  |  |  |  |
| Outstanding at March 31, 2026 | 617275 | $27.54 | 7.05 | $- |
| Exercisable at March 31, 2026 | 401138 | $33.13 | 6.17 | $- |

---

*Performance-Based Stock Option Awards*

We also grant stock options to selected executives with vesting contingent upon meeting certain Company-wide performance goals. The performance goals for options issued in 2024 are based on reaching a total recurring contract value target, measured at the end of the performance period, December 31, 2026. Vesting is also dependent upon remaining in our employment through the performance period. The performance awards issued in 2024 have a six-year contractual term. We recognize compensation expense prospectively from the date it is deemed probable that the performance goal will be met through the end of the performance period. We did not recognize compensation expense related to performance-based awards in 2025 or 2026 since achieving the performance goals was not deemed probable. There was no activity related to performance-based stock option awards during the three months ended March 31, 2026.

As of March 31, 2026, the total unrecognized compensation cost related to non-vested performance-based and service-based stock option awards was approximately $1.4 million which was expected to be recognized over a weighted average period of 1.6 years.

There was $139,000 and $132,000 of cash received from stock options exercised during the three-month periods ended March 31, 2026 and 2025, respectively. We recognized $245,000 and $171,000 of non-cash compensation expense for the three-month periods ended March 31, 2026, and 2025, respectively, which is included in selling, general, and administrative expenses.

*Non-vested Stock Awards and Restricted Stock Units*

No shares of non-vested restricted stock awards (RSAs) were granted during the three-month periods ended March 31, 2026 and 2025. At March 31, 2026 and December 31, 2025, there were 829,000 non-vested restricted stock awards outstanding with total remaining unrecognized compensation expense of $7.7 million expected to be recognized over a weighted average period of 2.1 years. We recognized non-cash compensation expense of $1.0 million for the three-month period ended March 31, 2026, related to non-vested stock, which is included in selling, general, and administrative expenses. No expense was recognized for the three-month period ended March 31, 2025.

We granted 160,000 restricted stock units (RSUs) during the three months ended March 31, 2026. No RSUs were granted in 2025. RSUs do not carry dividend or voting rights prior to vesting. At March 31, 2026, 160,000 RSUs were outstanding, with total remaining unrecognized compensation expense of $2.4 million expected to be recognized over a weighted-average period of 1.8 years. We recognized non-cash compensation expense of $331,000 for the three months ended March 31, 2026, related to RSUs, which is included in selling, general, and administrative expenses. No expense was recognized for the three-month period ended March 31, 2025.

------

[**Table of Contents**](#toc)

**(6)** **<u>GOODWILL AND OTHER INTANGIBLE ASSETS</u>**

The carrying amount of goodwill totaled $66,152 at March 31, 2026, and no impairments were recognized during the three month-period then ended.

Intangible assets consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | March 31,<br> 2026 | December 31,<br> 2025 |
| Non-amortizing intangible assets: |  |  |
| Indefinite trade name | $1191 | $1191 |
| Amortizing intangible assets: |  |  |
| Customer related | 9772 | 9772 |
| Technology | 2790 | 2790 |
| Trade names | 1572 | 1572 |
| Total amortizing intangible assets | 14134 | 14134 |
| Accumulated amortization | (13160) | (13098) |
| Other intangible assets, net | $2165 | $2227 |

---

**(7)** **<u>EARNINGS PER SHARE</u>**

Basic net income per share was computed using the weighted-average shares of common stock outstanding during the period.

Diluted net income per share was computed using the weighted-average shares of common stock and, if dilutive, the potential common stock outstanding during the period. Potential shares of common stock consist of the incremental common stock issuable upon the exercise of stock options and vesting of restricted stock. The dilutive effect of outstanding stock options and restricted stock units is reflected in diluted earnings per share by application of the treasury stock method.

We had 370,699 and 427,838 options of common stock for the three-month periods ended March 31, 2026, and 2025, respectively, which have been excluded from the diluted net income per share computation because their inclusion would be anti-dilutive. Performance-based stock option awards have not been included in the computation since the conditions have not been met.

---

| | | |
|:---|:---|:---|
|  | For the Three<br> Months Ended<br> March 31, 2026 | For the Three<br> Months Ended<br> March 31, 2025 |
|  | (In thousands, except per share data) | (In thousands, except per share data) |
| Numerator for net income per share – basic: |  |  |
| Net income | $3222 | $5787 |
| Allocation of distributed and undistributed income to unvested restricted stock shareholders | (133) |  |
| Net income attributable to common shareholders | 3089 | 5787 |
| Denominator for net income per share – basic: |  |  |
| Weighted average shares of common stock outstanding – basic | 21799 | 22972 |
| Net income per share – basic | $0.14 | $0.25 |
| Numerator for net income per share – diluted: |  |  |
| Net income attributable to common shareholders for basic computation | 3089 | 5787 |
| Denominator for net income per share – diluted: |  |  |
| Weighted average shares of common stock outstanding – basic | 21799 | 22972 |
| Weighted average effect of dilutive securities – stock options | 56 | 2 |
| Weighted average effect of dilutive securities – restricted stock units | 56 | 0 |
| Denominator for diluted earnings per share – adjusted weighted average shares | 21911 | 22974 |
| Net income per share – diluted | $0.14 | $0.25 |

---

------

[**Table of Contents**](#toc)

**(8)** **<u>Segment Information</u>**

The Company assesses segment reporting in accordance with ASC 280, *Segment Reporting*. Based on how the business is managed and the financial information reviewed by our Chief Operating Decision Maker ("CODM"), who is our Chief Executive Officer, the Company operates as one operating segment and one reportable segment.

The CODM evaluates the Company's performance and allocates resources based on consolidated net income, which is the primary measure used to assess results against forecasts and historical trends. Because the Company has a single operating segment, our segment results are identical to the amounts presented in our Consolidated Statements of Income, and we have no inter-segment revenues or transfers.

In addition to consolidated net income, the CODM is regularly provided supplemental information regarding certain management bonuses (when applicable), noncash stock compensation expense, and the related income tax, as presented below for the three months ending (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | March 31, 2026 | March 31, 2026 | March 31, 2025 | March 31, 2025 |
| Noncash stock compensation |  | 1608 |  | 171 |
| Tax benefit on noncash stock compensation |  | 262 |  | 43 |

---

------

[**Table of Contents**](#toc)

**(9)** **<u>Subsequent Event</u>**

On April 27, 2026, the Compensation and Talent Committee of our Board of Directors approved amendments to equity awards granted to certain executives in 2025. The amendments eliminated the Company's right to repurchase the shares underlying these awards if the executives' employment terminated under certain circumstances prior to the third anniversary of the respective grant dates. The impacted executives were also awarded bonuses intended to cover their anticipated tax obligations in connection with these amendments.

The amendments and related bonuses are expected to result in approximately $9.4 million of expense during the second quarter of 2026, consisting of (i) approximately $6.5 million of non-cash accelerated equity compensation expense, substantially all of which would otherwise have been recognized ratably through the second quarter of 2028, and (ii) approximately $2.9 million of cash bonus expense, primarily related to tax payments. The Company's effective tax rate for the second quarter and the remainder of 2026 is expected to be impacted by the non-deductibility of these amounts.

---

| | |
|:---|:---|
| **ITEM 2.** | **<u>Management</u>**<u>'</u>**<u>s Discussion and Analysis of Financial Condition and Results of Operations</u>** |

---

The following discussion of our results of operations and financial condition should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.

Our purpose is to humanize healthcare and support organizations in their understanding of each unique individual. Our commitment to Human Understanding® helps leading healthcare systems improve their operations through understanding each person they serve not as point-in-time insights, but as an ongoing relationship. Our end-to-end solutions enable our customers to understand what matters most to each person they serve – before, during, after, and beyond clinical encounters – to gain a longitudinal understanding of how life and health intersect, with the goal of developing lasting, trusting relationships. Our ability to measure what matters most and systematically capture, analyze, and deliver insights based on self-reported information from patients, families, and consumers is critical in today's healthcare market. We believe access to, analysis of, and acting on our extensive individual-driven information is increasingly valuable as healthcare providers need to better understand and engage the people they serve to create long-term relationships, build loyalty, and improve processes.

Our portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. We partner with customers across the continuum of healthcare services and believe this cross-continuum positioning is a unique and an increasingly important capability as the evolving healthcare landscape drives its constituents towards a more collaborative and integrated service model.

------

[**Table of Contents**](#toc)

**Results of Operations**

The following table sets forth, for the periods indicated, selected financial information derived from our condensed consolidated financial statements and the percentage change in such items versus the prior comparable period, as well as other key financial metrics. The discussion that follows the information should be read in conjunction with our condensed consolidated financial statements.

**Three Months Ended March 31, 2026, Compared to Three Months Ended March 31, 2025**

---

| | | | |
|:---|:---|:---|:---|
|  | (In thousands, except percentages)<br> Three Months Ended March 31, | (In thousands, except percentages)<br> Three Months Ended March 31, | Percentage<br> Increase<br> (Decrease) |
|  | 2026 | 2025 | 2026 over 2025 |
| Revenue | $34803 | $33551 | 4 |
| Direct expenses | 13646 | 13057 | 5 |
| Selling, general, and administrative | 13419 | 10356 | 30 |
| Depreciation and amortization | 2169 | 1542 | 41 |
| Operating income | 5569 | 8596 | (35) |
| Total other expense | (1190) | (873) | 36 |
| Provision for income taxes | 1157 | 1936 | (40) |
| Effective Tax Rate | 26% | 25% | 1 |
| Operating margin | 16% | 26% | (10) |
| Total Recurring Contract Value | $152070 | $134371 | 13 |
| Cash provided by operating activities | 7180 | 6646 | 8 |

---

*Revenue.* Revenue in the 2026 period increased compared to the 2025 period by $1.3 million. This was mainly from $0.6 million higher recurring revenue from existing customers compared to the prior year, and $0.5 million higher revenue from new customers, compared to the prior year.

*Direct expenses*. Direct expenses consist primarily of salaries and employee benefits, employee travel and lodging, materials, contract labor, third party software subscription costs, hosted customer conferences, and other direct expenses associated with revenue. Personnel costs within direct expenses are associated with individuals in product delivery, customer support, thought leadership, conference support, technology infrastructure, and product development. Direct expenses represented 39% of revenue for both 2026 and 2025. Direct expenses increased to $13.6 million in 2026 from $13.1 million in 2025, primarily driven by higher third-party software subscription costs and increased spending on IT contractor services related to continued investments in technology and development.

*Selling, general, and administrative expenses*. Selling, general, and administrative expenses consist of salaries and employee benefits, commission and amortization of deferred commission, stock-based compensation, employee travel and lodging, third party software subscription and platform costs, marketing costs, facility expenses, office expenses, fees for professional services, provision for credit losses, and other operational expenses. Personnel costs within selling, general, and administrative expenses are associated with individuals in sales, marketing, accounting, business development, human resources, administrative, product development, internal information systems, and executive management. Selling, general, and administrative expenses increased to $13.4 million for the three months ended March 31, 2026, from $10.4 million for the same period in 2025. The increase was primarily driven by $1.4 million of higher stock-based compensation related to executive leadership and approximately $0.5 million of executive salary expense that was not present in the prior-year period. The remaining increase was attributable to higher computer software subscription expenses to support ongoing technology investments, regulatory-related accruals, and the timing of corporate-related expenses.

*Depreciation and amortization*. Depreciation and amortization expenses increased in the 2026 period compared to the 2025 period due to the completion of our headquarters building renovations in June 2025.

*Operating income and margin*. Operating income decreased in the 2026 period compared to the 2025 period due to the increased compensation related to our executive leadership transition and increased investment in technology.

*Total other expense*. Total other expense increased in the 2026 period compared to the 2025 period due to higher interest expense due to a higher balance on the Delayed Draw Term Loan.

------

[**Table of Contents**](#toc)

*Provision for income taxes and effective tax rate*. Provision for income taxes decreased in the 2026 period compared to the 2025 period primarily due to decreased taxable income, partially offset by an increase in the effective tax rate. The effective tax rate increased in the 2026 period due to executive compensation subject to the deductibility limitations under Section 162(m), which did not affect the effective tax rate in the first quarter of 2025.

*Total Recurring Contract Value (TRCV)*. TRCV at March 31, 2026, was higher compared to March 31, 2025, primarily due to sales to new and existing customers and to improved retention of contracts with existing customers. We view TRCV as a leading indicator of our future revenue trends. TRCV represents the total annualized contract value of recurring amounts under customer contracts that are in effect or contractually committed as of the most recent quarter-end and are expected to be in force over the subsequent 12 months, based on contractual pricing and term provisions. TRCV is calculated using contracted recurring fees and assumes no upsells, downsells, price changes, early terminations, or non-renewals, unless we have been notified of such changes by the customer as of the measurement date. TRCV is an operating metric and is not a measure of revenue recognized under U.S. GAAP. The timing and amount of revenue we recognize under ASC 606 may differ from the pattern implied by TRCV due to allocation of transaction price and the timing of satisfaction of performance obligations. As a result, there is typically a lag between changes in TRCV and changes in our reported revenue. Generally, if we are able to sustain growth in TRCV, we would expect revenue growth to follow within subsequent periods, although intervening factors may affect this relationship.

**Recent Developments**

In April 2026, the Compensation and Talent Committee of our Board of Directors approved amendments to equity awards granted to certain executives in 2025. The amendments eliminated the Company's right to repurchase the shares underlying these awards if the executives' employment terminated under certain circumstances prior to the third anniversary of the respective grant dates. The impacted executives were also awarded bonuses intended to cover their anticipated tax obligations in connection with these amendments.

The amendments and related bonuses are expected to result in approximately $9.4 million of expense during the second quarter of 2026, consisting of (i) approximately $6.5 million of non-cash accelerated equity compensation expense, substantially all of which would otherwise have been recognized ratably through the second quarter of 2028, and (ii) approximately $2.9 million of cash bonus expense, primarily related to tax payments. The Company's effective tax rate for the second quarter and the remainder of 2026 is expected to be impacted by the non-deductibility of these amounts. The acceleration of equity compensation expense eliminates the impact of these awards on future periods.

**Non-GAAP Financial Measures**

In addition to consolidated GAAP financial measures, we review various non-GAAP financial measures that management believes to be important in the evaluation of its operating results and performance, including "Adjusted Net Income," "Adjusted Earnings per Share," "Adjusted EBITDA," "Adjusted EBITDA Margin," "Free Cash Flow," and "Free Cash Flow Margin."

We believe Adjusted Net Income, Adjusted Earnings per Share, Adjusted EBITDA, and Adjusted EBITDA Margin are helpful supplemental measures to assist management and investors in evaluating our operating results as (i) they exclude certain items that are unusual in nature or whose fluctuation from period to period do not necessarily correspond to changes in the operations of our business, and (ii) the exclusion of non-cash stock compensation is useful for investors applying certain valuation metrics and is consistent with the leverage ratio for our credit facility. Adjusted Net Income represents net income adjusted to add back certain management bonuses and non-cash stock compensation and the related tax. Adjusted EBITDA represents net income before interest, taxes, depreciation, amortization, certain management bonuses, and non-cash stock compensation items. Adjusted EBITDA Margin represents Adjusted EBITDA divided by our revenue.

We consider Free Cash Flow to be a measure that provides useful information to management and investors about our liquidity. Free Cash Flow does not represent residual cash flow available for discretionary expenditures. We define Free Cash Flow as net cash provided by operating activities less capital expenditures. Free Cash Flow Margin represents Free Cash Flow divided by our revenue.

We view Adjusted Net Income, Adjusted Earnings per Share, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, and Free Cash Flow Margin as operating performance measures. As such, we believe the most directly comparable GAAP financial measures to Adjusted Net Income and Adjusted Earnings per Share are GAAP Net Income and GAAP Earnings per Share, respectively, the most directly comparable GAAP financial measure to Adjusted EBITDA and Adjusted EBITDA Margin is GAAP Net Income and GAAP Net Income Margin, and the most directly comparable GAAP financial measure to Free Cash Flow and Free Cash Flow Margin is GAAP Net Cash Provided by Operating Activities and GAAP Net Cash Provided by Operating Activities Margin.

------

[**Table of Contents**](#toc)

Non-GAAP measures are supplemental financial measures of our performance and should not be considered substitutes for net income, earnings per share, or any other measure derived in accordance with GAAP. This information should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items or events being adjusted. In addition, other companies may use different measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP.

***Adjusted Net Income and Adjusted Earnings per Share***

The following table presents a reconciliation of GAAP net income and GAAP earnings per share to adjusted net income and adjusted earnings per share, respectively, for each of the periods indicated (in thousands excluding earnings per share):

---

| | | |
|:---|:---|:---|
|  | Three Months Ended March 31, | Three Months Ended March 31, |
|  | 2026 | 2025 |
| Net income | $3222 | $5787 |
| Add back: |  |  |
| Non-cash stock compensation | 1608 | 171 |
| Tax on stock compensation | (262) | (43) |
| Adjusted net income | $4568 | $5915 |
| Earnings per share of common stock, diluted | $0.14 | $0.25 |
| Adjusted earnings per share of common stock, diluted | $0.21 | $0.26 |
| Weighted average shares and share equivalents outstanding, diluted | 21911 | 22974 |

---

***Adjusted EBITDA and Adjusted EBITDA Margin***

The following table presents a reconciliation of GAAP net income and GAAP net income margin to adjusted EBITDA and adjusted EBITDA margin, respectively, for each of the periods indicated (in thousands):

---

| | | |
|:---|:---|:---|
|  | Three Months Ended March 31, | Three Months Ended March 31, |
|  | 2026 | 2025 |
| Net income | $3222 | $5787 |
| Add back: |  |  |
| Depreciation and amortization | 2169 | 1542 |
| Interest expense | 1255 | 899 |
| Income taxes | 1157 | 1936 |
| Non-cash stock compensation | 1608 | 171 |
| Adjusted EBITDA | $9411 | $10335 |
| Net income margin | 9.3% | 17.2% |
| Adjusted EBITDA margin | 27.0% | 30.8% |

---

------

[**Table of Contents**](#toc)

***Free Cash Flow and Free Cash Flow Margin***

The following table presents a reconciliation of GAAP net cash provided by operating activities and net cash provided by operating activities margin to free cash flow and free cash flow margin, respectively, for each of the periods indicated (in thousands):

---

| | | |
|:---|:---|:---|
|  | Three Months Ended March 31, | Three Months Ended March 31, |
|  | 2026 | 2025 |
| Net cash provided by operating activities | $7180 | $6646 |
| Less: |  |  |
| Capital expenditures | 1834 | 2986 |
| Free cash flow | $5346 | $3660 |
| Net cash provided by operating activities margin | 20.6% | 19.8% |
| Free cash flow margin | 15.4% | 10.9% |

---

**Liquidity and Capital Resources**

Our Board of Directors has established priorities for capital allocation, which include funding of innovation and growth investments, including merger and acquisition activity as well as internal projects, and returning capital to shareholders through dividends and share repurchases.

As of March 31, 2026, our principal sources of liquidity included $2.5 million of cash and cash equivalents, up to $30.0 million of unused borrowings under our Revolving Loan and an additional $27.6 million on our Delayed Draw Term Loan.

Our cash flows from operating activities primarily consist of net income adjusted for non-cash items including depreciation and amortization, deferred income taxes, share-based compensation, and the effect of working capital changes. Cash provided by operating activities increased primarily due to working capital changes, partially offset by a decrease in net income. Working capital changes were mainly driven by trade accounts receivable and prepaid expenses primarily due to timing of billings and payments, and higher deferred revenue. Cash provided by operating activities was also partially offset by an increase in net income net of non-cash items.

See the Condensed Consolidated Statements of Cash Flows included in this report for the detail of our operating cash flows.

We had a working capital deficit of $18.5 million and $16.4 million on March 31, 2026, and December 31, 2025, respectively. The change was primarily due to decreases in cash and cash equivalents and increases in accounts payable, deferred revenue, and income taxes payable. Cash and cash equivalents decreased mainly due to the payment of dividends and the repurchase of shares of our common stock for treasury. The decrease in cash and cash equivalents was partially offset by cash from operating activities. Our working capital is significantly impacted by our large deferred revenue balances which will vary based on the timing and frequency of billings on annual agreements. Notwithstanding our working capital deficit on March 31, 2026, we believe that our existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows will be sufficient to meet our projected capital and debt maturity needs for the foreseeable future.

Cash used in investing activities primarily consisted of capitalized internal-use software and purchases of property and equipment including computer software and hardware, building improvements, and furniture and equipment.

Cash used in financing activities consisted of payments of dividends on our common stock, payments on our Delayed Draw Term Loan, repurchases of common stock, and cash to pay contingent consideration related to our 2024 acquisition of Nobl Health.

------

[**Table of Contents**](#toc)

Our material cash requirements include the following contractual and other obligations:

*Dividends*

Cash dividends of $3.6 million were paid in the three months ended March 31, 2026. Additional dividends of $3.6 million were declared in the three months ended March 31, 2026, and paid in April 2026. The dividends were paid from cash on hand and borrowings on our Revolving Loan. Our Board of Directors considers whether to declare a dividend and the amount of any dividends declared on a quarterly basis.

*Capital Expenditures*

We paid cash of $1.8 million for capital expenditures in the three months ended March 31, 2026. These expenditures consisted primarily of computer hardware and software and costs related to software development for our Human Understanding® solutions.

*Debt* 

Our credit agreement (the "Credit Agreement"), includes (i) a $30.0 million revolving credit facility (the "Revolving Loan") and (ii) a $110.0 million delayed draw-down term facility (the "Delayed Draw Term Loan" and, together with the Revolving Loan, the "Credit Facilities"). The Delayed Draw Term Loan includes an accordion feature that, so long as no event of default exists or would exist after giving effect to such increase, allows us to request an increase in the Delayed Draw Term Loan of up to the lesser of (x) $25.0 million and (y) our EBITDA as of the preceding four fiscal quarters, exercisable in increments of $10.0 million (or the remaining available amount of the accordion, if less). We may use the Delayed Draw Term Loan to fund permitted future business acquisitions, repurchases of our common stock, capital expenditures, or payment of dividends and the Revolving Loan to fund ongoing working capital needs and for other general corporate purposes.

Interest accrues and is payable monthly at a floating rate equal to the one-month Term SOFR plus a percentage per annum determined by our cash flow leverage ratio, ranging from 2.25% to 2.75% (6.02% at March 31, 2026).

The outstanding balance on the Delayed Draw Term Loan was $78.4 million at March 31, 2026. Principal amounts outstanding are due and payable monthly during the term of the Delayed Draw Term Loan, in equal monthly installments to amortize the aggregate outstanding principal balance by (i) 5% during each of the first three years and (ii) 7.5% during each of the fourth and fifth years following the date of such loan. All outstanding principal and interest on the Delayed Draw Term Loan are due and payable in full at the maturity date, February 6, 2030. We had the availability to borrow an additional $27.6 million on the Delayed Draw Term Loan at March 31, 2026, excluding the accordion feature.

Principal amounts outstanding under the Revolving Loan are due and payable in full at maturity at February 6, 2028. As of March 31, 2026, we had no borrowings outstanding and the availability to borrow $30.0 million on the Revolving Loan. Our weighted average short-term borrowings for the three-month periods ended March 31, 2026, and 2025 were $1.9 million and $2.0 million, respectively. The weighted average interest rate on short-term borrowings during the three-month periods ended March 31, 2026, and 2025 was 6.04% and 6.67%, respectively.

We are obligated to pay ongoing unused commitment fees quarterly in arrears at a percentage per annum determined by our cash flow leverage ratio, ranging from 0.15% to 0.30%, based on the actual daily unused portions of the Revolving Loan and the Delayed Draw Term Loan, respectively.

The Credit Agreement is collateralized by substantially all of our assets, subject to permitted liens and other agreed exceptions, and contains customary representations, warranties, affirmative and negative covenants (including financial covenants), and events of default. The negative covenants include, among other things, restrictions regarding the incurrence of indebtedness and liens, repurchases of our common stock, and acquisitions, subject in each case to certain exceptions. Pursuant to the Credit Agreement, we are required to maintain a minimum fixed charge coverage ratio of 1.10x and a cash flow leverage ratio of 3.50x or less for all testing periods throughout the term of the Credit Facilities. As of March 31, 2026, we were in compliance with our financial covenants.

*Leases*

We have lease arrangements for certain computer, office, printing, and mail inserting equipment as well as office and data center space. As of March 31, 2026, we had fixed lease payments of $493,000 and $8,000 for operating and finance leases, respectively payable within 12 months.

------

[**Table of Contents**](#toc)

*Taxes*

The liability for gross unrecognized tax benefits related to uncertain tax positions was $2.3 million as of March 31, 2026. See Note 3, "Income Taxes", to the Condensed Consolidated Financial Statements contained in this report for income tax related information.

**Stock Repurchase Program**

In March 2026, our Board of Directors approved a stock repurchase program authorizing the repurchase up to $60.0 million of our outstanding common stock through March 31, 2028 (the "2026 Program"). Under this authorization, may repurchase shares from time to time in the open market, through privately negotiated transactions, and/or other means in compliance with the Securities and Exchange Act of 1934 and the rules and regulations thereunder. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of shares of common stock under this authorization. The timing, manner, price, and amount of any repurchases will be determined by the Company at its discretion, and will depend on a variety of factors, including business, economic and market conditions, prevailing stock prices, corporate and regulatory requirements, and other considerations. The repurchase program may be suspended or discontinued at any time.

During the three months ended March 31, 2026, we repurchased 109,701 shares of our common stock for an aggregate of $1.9 million.

**Critical Accounting Estimates**

There have been no changes to our critical accounting estimates described in the Annual Report on Form 10-K for the year ended December 31, 2025, that have a material impact on our Condensed Consolidated Financial Statements and the related Notes.

------

[**Table of Contents**](#toc)

---

| | |
|:---|:---|
| **ITEM 3.** | **<u>Quantitative and Qualitative Disclosures about Market Risk</u>**  |

---

There are no material changes to the disclosures regarding our market risk exposures made in its Annual Report on Form 10-K for the year ended December 31, 2025.

---

| | |
|:---|:---|
| **ITEM 4.** | **<u>Controls and Procedures</u>** |

---

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report, and our Chief Executive Officer and our Chief Financial Officer, have concluded that, as of the end of such period, our disclosure controls and procedures were effective.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Accordingly, effective internal control over financial reporting can only provide reasonable assurance of achieving its control objectives.

We have confidence in our internal controls and procedures. Nevertheless, our management, including our Chief Executive Officer and our Chief Financial Officer, does not expect that our disclosure procedures and controls or our internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. As a result of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all our control issues and instances of fraud, if any, have been detected.

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**PART II** – **Other Information**

---

| | |
|:---|:---|
| **ITEM 1.** | **<u>Legal Proceedings</u>** |

---

From time to time, we are involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss for such contingencies and recognizes a liability when a loss is probable and estimable. For additional information, see Note 1, under the heading "Commitments and Contingencies," to our condensed consolidated financial statements. Regardless of the final outcome, any legal proceedings, claims, inquiries and investigations, however, can impose a significant burden on management and employees, may include costly defense and settlement costs, and could cause harm to our reputation and brand, and other factors.

---

| | |
|:---|:---|
| **ITEM 1A.** | **<u>Risk Factors</u>** |

---

The significant risk factors known to us that could materially adversely affect our business, financial condition, or operating results are described in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025.

------

[**Table of Contents**](#toc)

---

| | |
|:---|:---|
| **ITEM 2.** | **<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>** |

---

Our Credit Agreement provides that, in order for us to pay dividends or repurchase our common stock, there must be no default or event of default existing or that would result from such payment and we must show that we would comply with the Credit Agreement's fixed charge coverage ratio and consolidated cash flow leverage ratio after giving pro forma effect to such payment.

The table below summarizes repurchases of common stock during the three months ended March 31, 2026.

---

| | | | | |
|:---|:---|:---|:---|:---|
| Period | Total<br> Number<br> of Shares<br> Purchased | Average<br> Price<br> Paid per<br> Share <sup>(1)</sup> | Total Number of<br> Shares Purchased<br> as Part of Publicly<br> Announced Plans<br> or Programs<sup>(2)</sup> | Approximate Dollar Value<br> of Shares that May<br> Yet Be Purchased<br> Under the Plans<br> or Programs<sup>(2)</sup> |
| Jan 1 – Jan 31, 2026 |  |  |  | $- |
| Feb 1 – Feb 28, 2026 |  |  |  |  |
| Mar 1 – Mar 31, 2026 | 109701 | 17.51 | 109701 | 58066938 |
| Total | 109701 |  | 109701 | $58066938 |

---

(1) The average price paid per share excludes excise tax incurred on stock repurchases. For the quarter ended March 31, 2026, excise tax expense totaled $17,624.

(2) In March 2026, our Board of Directors authorized the 2026 Program, which authorizes the repurchase up to $60.0 million of our outstanding common stock through March 31, 2028. During the three months ended March 31, 2026, we repurchased 109,701 shares of our common stock for an aggregate of $1.9 million.

---

| | |
|:---|:---|
| **ITEM 5.** | **Other Information** |

---

During the first quarter of 2026, no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.

------

[**Table of Contents**](#toc)

---

| | |
|:---|:---|
| **ITEM 6.** | **<u>Exhibits</u>**  |

---

The exhibits listed in the exhibit index below are filed as part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit**<br> **<u>Number</u>** | **<u>Exhibit Description</u>** |
| (3.1) | [<u>Certificate of Incorporation of the Company, effective June 30, 2021 \[Incorporated by reference to Exhibit 3.3 to the Company</u><u>'</u><u>s Current Report on Form 8-K filed on July 2, 2021 (File No. 001-35929)\]</u>](http://www.sec.gov/Archives/edgar/data/70487/000143774921016301/ex_261352.htm) |
| (3.2) | [<u>Certificate of Amendment to Certificate of Incorporation of the Company, dated April 15, 2026 \[Incorporated by reference to Exhibit 3.1 to the Company'</u><u>s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)\]</u>](http://www.sec.gov/Archives/edgar/data/70487/000143774926012850/ex_943656.htm) |
| (3.3) | [<u>Amended and Restated Bylaws of the Company as of April 15, 2026 \[Incorporated by reference to Exhibit 3.2 to the Company'</u><u>s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)\]</u>](http://www.sec.gov/Archives/edgar/data/70487/000143774926012850/ex_943657.htm) |
| (4.1) | [<u>Certificate of Incorporation of the Company, effective June 30, 2021 \[Incorporated by reference to Exhibit 3.3 to the Company'</u><u>s Current Report on Form 8-K filed on July 2, 2021 (File No. 001-35929)\]</u>](http://www.sec.gov/Archives/edgar/data/70487/000143774921016301/ex_261352.htm) |
| (4.2) | [<u>Certificate of Amendment to Certificate of Incorporation of the Company, dated April 15, 2026 \[Incorporated by reference to Exhibit 3.1 to the Company</u><u>'</u><u>s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)\]</u>](http://www.sec.gov/Archives/edgar/data/70487/000143774926012850/ex_943656.htm) |
| (4.3) | [<u>Amended and Restated Bylaws of the Company as of April 15, 2026 \[Incorporated by reference to Exhibit 3.2 to the Company</u><u>'</u><u>s Current Report on Form 8-K filed on April 20, 2026 (File No. 001-35929)\]</u>](http://www.sec.gov/Archives/edgar/data/70487/000143774926012850/ex_943657.htm) |
| (31.1)\*\* | [<u>Certification by the Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934</u>](ex_952771.htm) |
| (31.2)\*\* | [<u>Certification by the Chief Financial Officer (Principal Financial Officer) pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934</u>](ex_952770.htm) |
| (32)\*\*\* | [<u>Written Statement of the Chief Executive Officer (Principal Executive Officer) and the Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350</u>](ex_952769.htm) |
| (101) \*\* | Financial statements from the Quarterly Report on Form 10-Q of NRC Health for the quarter ended March 31, 2026, formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Notes to Condensed Consolidated Financial Statements, and (vi) document and entity information. |
| (104) \*\* | Cover Page Interactive Data File (formatted in the Inline XBRL and contained in Exhibit 101). |

---

\*\* Filed herewith

\*\*\* Furnished herewith

------

[**Table of Contents**](#toc)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **NRC HEALTH** | **NRC HEALTH** |
| Date: May 5, 2026 | By: | /s/ Trent S. Green |
|  |  | Trent S. Green |
|  |  | Chief Executive Officer<br> (Principal Executive Officer) |
| Date: May 5, 2026 | By: | /s/ Shane Harrison |
|  |  | Shane Harrison<br> Chief Financial Officer<br> (Principal Financial Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

Certification of Chief Executive Officer (Principal Executive Officer)

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Trent S. Green, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of NRC Health;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ Trent S. Green |
|  | Trent S. Green<br> Chief Executive Officer<br> (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

Certification of Chief Financial Officer (Principal Financial Officer)

Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934

I, Shane Harrison, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of NRC Health;

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 5, 2026 | /s/ Shane Harrison |
|  | Shane Harrison<br> Chief Financial Officer<br> (Principal Financial Officer) |

---

## Ex-32

**Exhibit 32**

**Certification Pursuant to 18 U.S.C. Section 1350**<br> **as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the accompanying Quarterly Report on Form 10-Q of NRC Health (the "Company") for the three-month period ended March 31, 2026 (the "Report"), I, Trent S. Green, Chief Executive Officer (Principal Executive Officer) of the Company, and I, Shane Harrison, Chief Financial Officer (Principal Financial Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, based on my knowledge, that:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| |
|:---|
| /s/ Trent S. Green  |
| Trent S. Green<br> Chief Executive Officer<br> (Principal Executive Officer) |
| /s/ Shane Harrison |
| Shane Harrison<br> Chief Financial Officer<br> (Principal Financial Officer) |
| Date: May 5, 2026 |

---

A signed original of this written statement required by Section 906 has been provided to NRC Health and will be retained by NRC Health and furnished to the Securities and Exchange Commission or its staff upon request.